A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma-Reference-Cited by-同舟云学术

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Published:2004-09-27 Issue:2 Volume:127 Page:165-172
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Jagannath S.,Barlogie B.,Berenson J.,Siegel D.,Irwin D.,Richardson P. G.,Niesvizky R.,Alexanian R.,Limentani S. A.,Alsina M.,Adams J.,Kauffman M.,Esseltine D.-L.,Schenkein D. P.,Anderson K. C.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2004.05188.x/fullpdf

Reference16 articles.

1. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids;Adams;Bioorganic and Medicinal Chemistry Letters,1998

2. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies;Aghajanian;Clinical Cancer Research,2002

3. The treatment of multiple myeloma;Alexanian;New England Journal of Medicine,1994

4. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Bladé;British Journal of Haematology,1998

5. Regulation of transcription factors by protein degradation;Desterro;Cellular and Molecular Life Sciences,2000

Cited by 621 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCAF15 control of cohesin dynamics sustains acute myeloid leukemia;Nature Communications;2024-07-03

2. Treatment outcomes of multiple myeloma in patients requiring renal replacement therapy;Journal of Renal Injury Prevention;2024-04-04

3. Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report;Cureus;2024-03-26

4. Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma;2024-03-05

5. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12